Tirzepatide is a dual GIP and GLP-1 receptor agonist used for the treatment of type 2 diabetes mellitus
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease
Choosing the optimal injection site and rotating locations also minimizes reactions over time
What it does is it seems to move the needle so patients can become more functional, but they may still need some fine tuning with the other medication, he tells WIRED
They can determine if the reaction is likely due to tirzepatide or something else, like another medication, skincare product, or infection
This results in a reduced desire to eat, helping individuals control their food intake